Comparative Effectiveness and Safety of Anti–Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn’s Disease-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparative Effectiveness and Safety of Anti–Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn’s Disease

Published:2016-08 Issue:8 Volume:14 Page:1120-1129.e6
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Singh Siddharth,Heien Herbert C.,Sangaralingham Lindsey R.,Schilz Stephanie R.,Kappelman Michael D.,Shah Nilay D.,Loftus Edward V.

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference18 articles.

1. Tumor necrosis factor inhibitors for inflammatory bowel disease;Nielsen;N Engl J Med,2013

2. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

3. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007

4. Certolizumab pegol for the treatment of Crohn's disease;Sandborn;N Engl J Med,2007

5. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial;Sandborn;Ann Intern Med,2007

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Inflammatory Bowel Disease with Biologics in Japan: A Single-Center, Retrospective Pharmacoeconomic Study;Biological and Pharmaceutical Bulletin;2024-01-20

2. Sustainability of biologic treatment in paediatric patients with Crohn’s disease: population-based registry analysis;Pediatric Research;2023-11-27

3. The role of inflammation in autoimmune disease: a therapeutic target;Frontiers in Immunology;2023-10-04

4. Durability of the First Biologic in Patients with Crohn’s Disease: A Nationwide Study from the epi-IIRN;Journal of Crohn's and Colitis;2023-07-19

5. Intestinal complications in patients with Crohn’s disease in the Brazilian public healthcare system between 2011 and 2020;World Journal of Clinical Cases;2023-05-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3